Venturelab's series about Switzerland’s most inspiring entrepreneurs and founders continues with Danuta Cichocka, the co-founder and CEO of Resistell AG.

The Muttenz-based biotech startup proposes an alternative to culture-based antibiograms, the current gold standard in antibiotic susceptibility testing. The EPFL spin-off offers a diagnostic device, the rapid AST method, which is based on the detection of movement caused by living bacterial cells. The new method reduces the time taken to get a result from days to minutes, shows which specific antibiotic is effective against the bacteria, and significantly improves the chances of patients’ survival.

published by:
Venturelab's series about Switzerland’s most inspiring entrepreneurs and founders continues with Danuta Cichocka, the co-founder and CEO of Resistell AG.